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A Double-Blind, Placebo-Controlled Trial
of Ruxolitinib for Myelofibrosis
Srdan Verstovsek, M.D., Ph.D., Ruben A. Mesa, M.D., Jason Gotlib, M.D.,
Richard S. Levy, M.D., Vikas Gupta, M.D., John F. DiPersio, M.D., Ph.D.,
John V. Catalano, M.D., Michael Deininger, M.D., Ph.D., Carole Miller, M.D.,
Richard T. Silver, M.D., Moshe Talpaz, M.D., Elliott F. Winton, M.D.,
Jimmie H. Harvey, Jr., M.D., Murat O. Arcasoy, M.D., Elizabeth Hexner, M.D.,
Roger M. Lyons, M.D., Ronald Paquette, M.D., Azra Raza, M.D.,
Kris Vaddi, Ph.D., Susan Erickson-Viitanen, Ph.D., Iphigenia L. Koumenis, M.S.,
William Sun, Ph.D., Victor Sandor, M.D., and Hagop M. Kantarjian, M.D.

A BS T R AC T
background

Ruxolitinib, a selective inhibitor of Janus kinase (JAK) 1 and 2, has clinically significant activity in myelofibrosis.
methodS

In this double-blind trial, we randomly assigned patients with intermediate-2 or highrisk myelofibrosis to twice-daily oral ruxolitinib (155 patients) or placebo (154 patients).
The primary end point was the proportion of patients with a reduction in spleen volume of 35% or more at 24 weeks, assessed by means of magnetic resonance imaging.
Secondary end points included the durability of response, changes in symptom burden (assessed by the total symptom score), and overall survival.
resulTS

The primary end point was reached in 41.9% of patients in the ruxolitinib group as
compared with 0.7% in the placebo group (P<0.001). A reduction in spleen volume was
maintained in patients who received ruxolitinib; 67.0% of the patients with a response
had the response for 48 weeks or more. There was an improvement of 50% or more in
the total symptom score at 24 weeks in 45.9% of patients who received ruxolitinib as
compared with 5.3% of patients who received placebo (P<0.001). Thirteen deaths occurred in the ruxolitinib group as compared with 24 deaths in the placebo group
(hazard ratio, 0.50; 95% confidence interval, 0.25 to 0.98; P = 0.04). The rate of discontinuation of the study drug because of adverse events was 11.0% in the ruxolitinib
group and 10.6% in the placebo group. Among patients who received ruxolitinib, anemia and thrombocytopenia were the most common adverse events, but they rarely led
to discontinuation of the drug (in one patient for each event). Two patients had transformation to acute myeloid leukemia; both were in the ruxolitinib group.
conclusionS

Ruxolitinib, as compared with placebo, provided significant clinical benefits in
patients with myelofibrosis by reducing spleen size, ameliorating debilitating
myelofibrosis-related symptoms, and improving overall survival. These benefits
came at the cost of more frequent anemia and thrombocytopenia in the early part
of the treatment period. (Funded by Incyte; COMFORT-I ClinicalTrials.gov number,
NCT00952289.)
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yelofibrosis, a myeloproliferative
neoplasm, is manifested by abnormal
blood counts (anemia, thrombocytosis
or thrombocytopenia, and leukocytosis or leukopenia), splenomegaly, and debilitating symptoms
(e.g., fatigue, weakness, abdominal pain, cachexia,
weight loss, pruritus, night sweats, and bone pain),
which are thought to be caused by the combined
effects of massive splenomegaly and elevated levels
of proinflammatory cytokines.1 Survival ranges
from approximately 2 to 11 years, depending on
defined prognostic factors.2 Traditional therapeutic
options, including splenectomy, have limited benefit.3 Although allogeneic stem-cell transplantation
may cure myelofibrosis, few patients are eligible for
this treatment.
Although the gain-of-function mutation in the
gene encoding Janus kinase (JAK) 2 (JAK2 V617F)
is present in approximately 50% of patients with
primary myelofibrosis, other mechanisms of direct
or indirect activation of the intracellular JAK–
signal transducer and activator of transcription
(STAT) pathway are known,4 suggesting that dysregulation of this pathway is a central pathogenic
component in myelofibrosis, regardless of the mutational status of JAK2. Also, proinflammatory
cytokines that play an important role in myelofibrosis signal through JAK 1 (JAK1) and JAK2.5
In a phase 1–2 trial of ruxolitinib (INCB018424,
Incyte), a potent inhibitor of JAK1 and JAK2,6,7
patients with myelofibrosis had durable reductions
in splenomegaly and improvements in myelofibrosis-related symptoms, regardless of their status
with respect to the JAK2 V617F mutation. To further evaluate the efficacy and safety of ruxolitinib, we conducted the Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment I
(COMFORT-I), a randomized, double-blind, placebo-controlled trial involving patients with intermediate-2 or high-risk myelofibrosis.

Me thods
PATIENTS

Patients were eligible for the study if they were
18 years of age or older and had primary myelofibrosis, post–polycythemia vera myelofibrosis, or
post–essential thrombocythemia myelofibrosis according to 2008 World Health Organization criteria,8 with a life expectancy of 6 months or longer,
an International Prognostic Scoring System (IPSS)
score2 (see Table S1 in the Supplementary Appendix, available with the full text of this article at
800
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NEJM.org) of 2 (intermediate-2 risk) or 3 or more
(high risk), an Eastern Cooperative Oncology Group
performance status9 of 3 or less (on a scale from
0 to 5, with higher scores indicating greater disability; see the Supplementary Appendix for further
details), less than 10% peripheral-blood blasts,
an absolute peripheral-blood CD34+ cell count of
more than 20×106 per liter, a platelet count of
100×109 per liter or more, and palpable splenomegaly (≥5 cm below the left costal margin). Patients had disease that was refractory to available
therapies, had side effects requiring their discontinuation, or were not candidates for available therapies and had disease requiring treatment. The trial
protocol, which describes in detail the inclusion
and exclusion criteria and other information about
the trial design, as well as the statistical analysis
plan, is available at NEJM.org.
Study Oversight

The protocol was approved by the institutional review board at each participating site. The study was
conducted in accordance with the International
Conference on Harmonization guidelines for Good
Clinical Practice. All patients provided written informed consent.
Data were collected by the academic investigators and analyzed by the sponsor of the study,
Incyte. The sponsor, in collaboration with the academic investigators, interpreted the data. The first
author and an author who was an employee of the
sponsor wrote the initial draft of the manuscript,
with assistance from a medical writer who was
paid by the sponsor. All the authors contributed to
subsequent drafts and made the decision to submit
the article for publication. All the authors vouch for
the accuracy and completeness of the reported data
and for the fidelity of this report to the protocol.
STUDY DESIGN AND TREATMENT

This randomized, double-blind, placebo-controlled,
phase 3 trial was conducted at 89 sites in the United States, Australia, and Canada. Patients were
randomly assigned in a 1:1 ratio to receive oral
ruxolitinib phosphate tablets or matched placebo.
The starting dose of ruxolitinib depended on the
baseline platelet count: 15 mg twice daily for a
platelet count of 100×109 to 200×109 per liter and
20 mg twice daily for a count that exceeded
200×109 per liter. The dose was adjusted for lack of
efficacy or excess toxicity as specified in the protocol (see the Supplementary Appendix). Unblinding
of the study-drug assignments and crossover from
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placebo to ruxolitinib were permitted for protocoldefined worsening splenomegaly (see the Supplementary Appendix). The prospectively defined cutoff point for data analysis occurred when half the
patients remaining in the study had completed the
week 36 visit and when all the patients had completed the week 24 evaluation or discontinued treatment. After crossover, data for patients who were
initially assigned to placebo were not included in
the analyses, except for the intention-to-treat analysis of overall survival.
The primary end point was the proportion of
patients with a reduction of 35% or more in spleen
volume from baseline to week 24, measured by
means of magnetic resonance imaging or computed tomography. Secondary end points included
the duration of the reduction in spleen volume; the
proportion of patients with a reduction in the total
symptom score of 50% or more from baseline to
week 24, as assessed with the modified Myelofibrosis Symptom Assessment Form (MFSAF), version 2.0 (see the Supplementary Appendix)10,11;
the change in the total symptom score from baseline to week 24; and overall survival. The analysis
of overall survival was updated at the time of a
planned data-collection cutoff 4 months after the
primary analysis. Patients completed the MFSAF
every night; this electronic diary was used to evaluate symptoms of night sweats, itching, abdominal
discomfort, pain under the ribs on the left side, a
feeling of fullness (early satiety), muscle or bone
pain, and inactivity. Scores ranged from 0 (“absent” symptoms) to 10 (“worst imaginable” symptoms), and the total symptom score was the sum
of the individual scores, excluding inactivity. Exploratory end points included changes in body
weight and the JAK2 V617F allele burden, achievement of independence from transfusions,12 and
additional patient-reported outcomes (see the Supplementary Appendix).
Statistical Analysis

The study was designed to enroll 240 patients, providing 97% power to detect a treatment difference
in spleen-volume response at a two-sided alpha
level of 0.05, assuming a response rate of 30% or
more for ruxolitinib and a response rate of 10% or
less for placebo. Analyses were conducted in accordance with the intention-to-treat principle. For all
applicable variables, however, patients with missing
baseline values were excluded from the analyses of
change and percent change from baseline. In the
analyses of change from baseline to week 24, pan engl j med 366;9

tients who discontinued the study drug or crossed
over before week 24 were counted as not having a
response (for response measures of a reduction in
spleen volume and symptom improvement). Secondary efficacy variables were tested in a fixedsequence testing procedure at an alpha level of
0.05. The durability of spleen response and survival were analyzed with the use of the Kaplan–
Meier method.

R e sult s
PATIENTS

From September 2009 through April 2010, a total
of 309 patients were enrolled: 155 were randomly assigned to ruxolitinib, and 154 were randomly
assigned to placebo. Baseline characteristics were
similar in the two groups (Table 1). The median
spleen volume was more than 2500 cm3 (>10 times
the median normal spleen volume of 200 cm3).13-15
A total of 38.2% of the patients had IPSS intermediate-2–risk disease, and 61.2% had high-risk
disease.
At the time of the prospectively defined data
cutoff (median follow-up, 32 weeks), 134 patients
in the ruxolitinib group (86.5%) and 78 in the placebo group (50.6%) were receiving the randomly
assigned study drug. Thirty-six patients in the placebo group (23.4%) crossed over to ruxolitinib
(16 before and 20 after week 24; see the Supplementary Appendix.)
EFFICACY

Spleen Size

The proportion of patients with a reduction of
35% or more in spleen volume at week 24 (primary
end point) was 41.9% in the ruxolitinib group as
compared with 0.7% in the placebo group (odds
ratio, 134.4; 95% confidence interval [CI], 18.0 to
1004.9; P<0.001) (Fig. 1A). Additional prespecified analyses showed that among the patients for
whom baseline and week 24 data were available,
the 139 patients receiving ruxolitinib had a mean
reduction in spleen volume of 31.6% (median,
33.0%) at week 24; the 106 patients receiving
placebo had a mean increase of 8.1% (median,
8.5%). Almost all patients receiving ruxolitinib had
some degree of reduction in spleen volume (Fig.
1B). The majority of patients receiving placebo
had spleen growth. Changes in palpable spleen
length in the ruxolitinib and placebo groups mirrored the changes in spleen volume. The reduction in spleen volume was durable with continued
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Table 1. Baseline Characteristics of the Patients.*
Variable

Ruxolitinib (N = 155)

Placebo (N = 154)

Median age (range) — yr

66 (43–91)

70 (40–86)

Male sex — % of patients

51.0

57.1

Primary myelofibrosis

45.2

54.5

Post–polycythemia vera myelofibrosis

32.3

30.5

Post–essential thrombocythemia myelofibrosis

22.6

14.3

High

58.1

64.3

Intermediate 2

41.3

35.1

67.1

56.5

Median platelet count (range) — ×10−9/liter

262 (81–984)

238 (100–887)

Median hemoglobin (range) — g/liter

105 (66–170)

105 (35–173)

Myelofibrosis subtype — % of patients

IPSS risk status — % of patients

Previous hydroxyurea use — % of patients

Median palpable spleen length (range) — cm

16 (0–33)†

16 (5–34)

Median spleen volume (range) — cm3

2598 (478–7462)

2566 (521–8881)

JAK2 V617F–positive — % of patients

72.9

79.9

* There were no significant differences between the two groups with the exception of age (P<0.05). IPSS denotes
International Prognostic Scoring System.
† One patient had a baseline spleen length recorded as nonpalpable in error but had a prior measurement of 16 cm and
a baseline spleen volume of 2450 cm3.

therapy (Fig. 1C). For this secondary end point,
among patients who had a reduction of 35% or
more in spleen volume, 67.0% (95% CI, 46.4 to
81.1) had a reduction in spleen volume that was
maintained for 48 weeks or more (loss of response
was defined as a reduction of <35% from baseline and an increase of ≥25% from the nadir).
Symptoms and Other Patient-Reported Outcomes

The proportion of patients with a reduction of 50%
or more in the total symptom score from baseline
to week 24, a prespecified secondary end point,
was significantly higher in the ruxolitinib group
than in the placebo group (45.9% vs. 5.3%; odds
ratio, 15.3; 95% CI, 6.9 to 33.7; P<0.001). Additional prespecified analyses showed that among
the patients for whom baseline and week 24 data
were available, the 129 patients receiving ruxolitinib had a mean improvement of 46.1% (median,
56.2%) in the total symptom score at week 24;
the 103 patients receiving placebo had a mean
worsening of 41.8% (median, 14.6%) in the score
(P<0.001). The improvement was rapid and was
maintained over the 24-week period during which
symptom data were collected (Fig. 2A). Most patients who received ruxolitinib had improvement
in symptoms; the majority of patients who received
placebo had worsening of symptoms (Fig. 2B).
802
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A post hoc analysis showed that patients who
received ruxolitinib had improvement in each individual symptom assessed on the MFSAF (Fig.
2C), whereas symptoms worsened in the placebo
group (P<0.01 for all comparisons with placebo).
Prespecified analyses were conducted to crossvalidate the modified MFSAF, version 2.0. The
Patient Global Impression of Change and other
patient-reported outcomes mirrored changes in
symptom scores (Fig. S3A, S3B, and S3C in the
Supplementary Appendix). Patients who received
ruxolitinib had weight gain, whereas those receiving placebo had weight loss (Fig. S4 in the Supplementary Appendix). In the ruxolitinib group, 62.7%
of patients with a reduction in spleen volume of
35% or more had improvement of 50% or more in
spleen-related symptoms (as indicated by the sum
of MFSAF scores for abdominal discomfort, pain
under the ribs on the left side, and a feeling of
fullness [early satiety]); however, this level of improvement also occurred in 46.9% of patients with
a reduction in spleen volume of less than 35%. An
additional post hoc analysis showed an improvement of 50% or more in nonabdominal symptoms
(night sweats, bone or muscle pain, and pruritus)
in 58.6% of patients with reductions in spleen
volume of 35% or more and in 54.1% of patients
with reductions in spleen volume of less than 35%.
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Figure 1. Change in Spleen Volume.
Panel A shows the results of the intention-to-treat analysis of the percentage of patients in each study group
who reached the primary end point of a reduction of
35% or more in spleen volume as assessed by means
of magnetic resonance imaging (MRI) or computed
tomography (CT). Patients who discontinued the study
drug before week 24 or crossed over before week 24 were
counted as not having had a response. Only patients
with baseline data were included in this analysis. I bars
denote 95% confidence intervals. CI denotes confidence
interval. Panel B shows the percent change from baseline in spleen volume at week 24 (in 139 patients in the
ruxolitinib group and 106 in the placebo group) or at
the last evaluation before week 24 (in 16 patients in the
ruxolitinib group and 47 in the placebo group). Data for
1 patient with a missing baseline value are not included
on the graph. Most patients in the ruxolitinib group
(150 of 155) had a reduction in spleen volume, whereas most patients in the placebo group had either an increase in spleen volume (102 of 153 patients) or no change
(15 of 153 patients). Panel C shows the median percent
change in spleen volume as assessed by means of MRI
or CT over time. Reductions in spleen volume were apparent at the first on-study measurement at 12 weeks
and were maintained over the course of the study. The
upper edge of each I bar corresponds to the 75th percentile, and the lower edge to the 25th percentile.

A
Patients with ≥35% Reduction
in Spleen Volume (%)

60

Odds ratio, 134.4 (95% CI, 18.0–1004.9)
P<0.001

41.9
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0
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B

Change in Spleen Volume
from Baseline (%)
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0
−20
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−40
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−80

Individual Patients

C
40

Median Change in Spleen Volume
from Baseline (%)

In a post hoc analysis of subgroups, mean changes
in spleen volume among patients with the JAK2
V617F mutation were −34.6% in the ruxolitinib
group and 8.1% in the placebo group; the corresponding changes among patients without the mutation were −23.8% and 8.4% (P value for interaction, 0.07). The changes in the total symptom score
among patients with the JAK2 V617F mutation were
−52.6% (improvement) in the ruxolitinib group and
42.8% (worsening) in the placebo group, and the
changes among those without the mutation were
−28.1% and 37.2%, respectively (P = 0.11 for interaction). Across myelofibrosis subtypes (primary
myelofibrosis, post–polycythemia vera myelofibrosis, and post–essential thrombocythemia myelofibrosis), patients who received ruxolitinib had a
decrease in spleen volume and improvement in the
total symptom score; patients receiving placebo
had increases in spleen volume (P = 0.52 for interaction) and worsening of the total symptom score
(P = 0.46 for interaction) (Fig. S5A and S5B in the
Supplementary Appendix).

20

Placebo

0
−20
−40
Ruxolitinib

−60
−80

Baseline

12

24

36

48

69
46

16
13

Weeks
No. of Patients
Ruxolitinib
Placebo

148
132

139
106

and 21.5% at week 48; patients who received placebo had a mean increase of 3.5% at week 24 and
6.3% at week 48 (Fig. S6 in the Supplementary
Appendix). Furthermore, patients receiving ruxolitinib had reductions in plasma levels of C-reactive
protein and the proinflammatory cytokines tumor
Biomarkers
In a prespecified analysis of biomarkers, patients necrosis factor α and interleukin-6, and they had
who received ruxolitinib had mean reductions in increases in levels of plasma leptin and erythrothe JAK2 V617F allele burden of 10.9% at week 24 poietin (Fig. S7 in the Supplementary Appendix).
n engl j med 366;9
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Figure 2. Change in Symptom Scores.
Panel A shows the results of an intention-to-treat analysis
of the proportion of patients with at least a 50% reduction
in the total symptom score over time (each value plotted
represents the moving average for the previous 7 days).
Patients who discontinued the study drug or for whom
data were missing were considered not to have had a response. The majority of responses occurred rapidly, within the first 4 weeks after treatment. Only patients with
baseline data were included in this analysis. Panel B
shows the percent change from baseline in the total
symptom score at week 24 (in 129 patients in the ruxolitinib group and 103 patients in the placebo group) and
at the last evaluation during receipt of the randomly assigned study drug (in 16 patients in the ruxolitinib group
and 42 patients in the placebo group). Five patients with
a baseline score of 0, 8 patients with missing baseline values, and 6 patients with insufficient data after baseline
are not included. Whereas most patients who received
ruxolitinib had a reduction in the total symptom score,
the majority of patients who received placebo had a worsening of symptoms (worsening in the total symptom
score of ≥150% is shown as 150%). Panel C shows the
mean percent change in the score for each symptom in
the modified Myelofibrosis Symptom Assessment Form,
version 2.0. All symptoms improved in the ruxolitinib
group and worsened in the placebo group (P<0.01 for all
comparisons with placebo). T bars denote standard errors.

60.0
(N=97)

14 deaths in the placebo group (9.1%) (hazard ratio,
0.67; 95% CI, 0.30 to 1.50; P = 0.33). Subsequently, a
survival analysis based on a planned data cutoff
with 4 additional months of follow-up (median
follow-up, 51 weeks) revealed a significant survival
advantage for patients who received ruxolitinib,
with 13 deaths in the ruxolitinib group (8.4%) and
24 deaths in the placebo group (15.6%) (hazard
ratio, 0.50; 95% CI, 0.25 to 0.98; P = 0.04) (Fig. 3).
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A total of 155 patients in the ruxolitinib group and
151 in the placebo group received at least one
0
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and 87 in the placebo group; study discontinuation
and crossover to ruxolitinib accounted for lower
exposure in the placebo group. Seventeen patients
who received ruxolitinib (11.0%) and 16 patients
who received placebo (10.6%) discontinued the
study treatment because of adverse events (of any
grade). Twenty deaths occurred during the study or
within 28 days after the last dose was administered
Overall Survival
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Figure 3. Overall Survival.
Kaplan–Meier estimates of overall survival, including 4 months of additional follow-up after the primary analysis,
are shown. There were 13 deaths in the ruxolitinib group (8.4%) and 24 deaths in the placebo group (15.6%) during
a median follow-up period of 51 weeks. Tick marks indicate censoring times for individual patients.

detailed information). Principal causes of death in
the ruxolitinib group were muscle weakness and
general deterioration, subdural hematoma, renal
failure, non–small-cell lung cancer, acute myeloid
leukemia (AML), pneumonia (in 2 patients), and
sepsis (in 2 patients). Principal causes of death in
the placebo group were staphylococcal infection,
gastrointestinal hemorrhage, intestinal perforation, multiorgan failure, pneumonia, sepsis (in
2 patients), and disease progression (in 4 patients).
Overall, nonhematologic adverse events occurred at a similar rate in the two groups. Events
that occurred more frequently in the ruxolitinib
group were ecchymosis, dizziness, and headache
(predominantly grade 1 or 2) (Table 2). The most
common grade 3 or 4 nonhematologic adverse
events (abdominal pain, fatigue, and dyspnea) occurred more frequently in the placebo group.
Anemia and thrombocytopenia were the most
frequent hematologic adverse events (overall and
grade 3 or 4 events) (Table 2) and a reason for
treatment discontinuation in one patient in each
study-drug group for each event. About half of all
grade 3 or 4 adverse events of anemia in the ruxolitinib group occurred during the first 8 weeks
of therapy. The mean hemoglobin level in patients
who received ruxolitinib reached a nadir of 95 g
per liter after approximately 8 to 12 weeks of
therapy (Fig. S8 in the Supplementary Appendix),
n engl j med 366;9

with an increase by week 24 to a new steady state
(101 g per liter). The monthly prevalence of grade
3 or 4 anemia and the proportion of patients requiring transfusions (1 or more units of red cells)
also followed a pattern that was consistent with
changes in the hemoglobin level over time (Fig.
S9A and S9B in the Supplementary Appendix). According to the response criteria of the International Working Group for Myelofibrosis Research
and Treatment, 41.2% of patients in the ruxolitinib
group and 46.9% of patients in the placebo group
who were dependent on transfusions at baseline
were classified as transfusion-independent during
the study (Table S4 in the Supplementary Appendix). In the ruxolitinib group, patients with newonset grade 3 or 4 anemia had improvements in
symptoms and reductions in spleen volume that
were similar to those in patients without anemia
(Fig. 9C and 9D in the Supplementary Appendix).
Approximately half the grade 3 or 4 thrombocytopenia events (11 of 20) occurred during the
first 8 weeks of treatment (Fig. S10 in the Supplementary Appendix) and led to dose adjustments or
brief treatment interruptions. Five patients had
more than one episode of grade 3 or 4 thrombocytopenia. Grade 3 episodes of bleeding (terms for
bleeding events are described in the Supplementary
Appendix) occurred in 2.6% of patients who received ruxolitinib and in 2.0% of patients who
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The

n e w e ng l a n d j o u r na l

Ruxolitinib (N = 155)
All
Grades

Grade
3 or 4

Placebo (N = 151)
All
Grades

Grade
3 or 4

percent of patients
Nonhematologic
Fatigue

25.2

5.2

33.8

6.6

Diarrhea

23.2

1.9

21.2

0

Peripheral edema

18.7

0

22.5

Ecchymosis

18.7

0

9.3

Dyspnea

17.4

1.3

17.2

Dizziness

14.8

0.6

6.6

Nausea

14.8

0

19.2

Headache

14.8

0

5.3

0

Constipation

12.9

0

11.9

0

Vomiting

12.3

0.6

9.9

0.7

Pain in extremity

12.3

1.3

9.9

0

Insomnia

11.6

0

9.9

0

Arthralgia

11.0

1.9

8.6

0.7

Pyrexia

11.0

0.6

7.3

0.7

Abdominal pain

10.3

2.6

41.1

11.3

Anemia

96.1

45.2

86.8

19.2

Thrombocytopenia

69.7

12.9

30.5

1.3

Neutropenia

18.7

7.1

4.0

2.0

1.3
0
4.0
0
0.7

Discussion

Hematologic abnormalities*

* Hematologic abnormalities are based on laboratory values. The data shown
are for events of the worst grade during the study, regardless of whether this
grade was a change from the baseline grade.

received placebo. Grade 4 episodes of bleeding
occurred in 1.3% of patients who received ruxolitinib and in 1.3% of patients who received placebo. Bruising (bleeding events related to skin and
subcutaneous tissue) (see the Supplementary Appendix) was assessed separately. A total of 23.2%
of patients who received ruxolitinib and 14.6% of
patients who received placebo had bruising; all
events were grade 1 or 2 except for one grade
3 event in the ruxolitinib group.
Among patients in whom the study drug was
interrupted, symptoms (assessed by means of the
total symptom score) returned to baseline levels
over a period of approximately 1 week (Fig. S11 in
the Supplementary Appendix). Adverse events of
grade 3 or higher developed in 8 of 49 patients in
the ruxolitinib group (16.3%) and in 7 of 54 patients in the placebo group (13.0%) after interruption of the study drug and in 12 of 21 patients in
the ruxolitinib group (57.1%) and 17 of 37 patients
in the placebo group (45.9%) after discontinuation.
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There was no clear pattern in these events to suggest a specific withdrawal effect (Tables S5 and S6
in the Supplementary Appendix).
Two patients in the ruxolitinib group had a
transformation to AML during the study: one patient with 7% bone marrow blasts at baseline and
a history of breast cancer had AML transformation
after 8 months in the study; the second patient
entered the study with 2% bone marrow blasts and
a trisomy 8 chromosomal abnormality at baseline
and had AML transformation after 5 months in the
study. There were no transformations in the placebo group.

Table 2. Adverse Events Observed in 10% or More of Patients Who Received
Ruxolitinib.
Event

of

In this study, ruxolitinib therapy was significantly
more effective than placebo with respect to all primary and secondary efficacy end points, as well as
in an updated analysis of overall survival. In the
ruxolitinib group, 41.9% of patients met the defined response threshold of a reduction of 35% or
more in spleen volume, and nearly all the patients
had some reduction in spleen volume. Reductions
in spleen volume were durable; 67.0% of patients
with a response had this response for 48 weeks or
longer with continued therapy.
Improvements in symptoms were measured
with the use of the modified MFSAF, version 2.0,
diary, a tool designed specifically to assess symptoms of myelofibrosis. The majority of patients
had improvements in symptoms, which occurred
even in patients who did not have a reduction in
spleen volume of 35% or more. In contrast, most
patients who received placebo had progressive
splenomegaly and worsening of myelofibrosisrelated symptoms. Changes in symptoms recorded with the MFSAF were directionally consistent
with the assessments made with other validated
and common patient-reported outcome instruments used in this study.
Anemia and thrombocytopenia were more
common in patients who received ruxolitinib than
in patients who received placebo. These adverse
events were manageable, as evidenced by the low
discontinuation rate (one patient in each group for
each event). Thrombocytopenia rarely recurred at
a grade 3 or 4 level after appropriate dose modifications and was not associated with an increase
in bleeding events, although bruising was more
common in the ruxolitinib group. The prevalence
of grade 3 or 4 anemia peaked after approximately
8 to 12 weeks of ruxolitinib therapy, subsequently
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decreasing to levels similar to those in patients managed with dose modification. These findings
who received placebo. In the ruxolitinib group, show that ruxolitinib is an effective therapy for
patients with new-onset grade 3 or 4 anemia had myelofibrosis.
Supported by Incyte.
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In conclusion, ruxolitinib was associated with
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We thank Kelly Reith of Incyte for editorial assistance with an
prominent manifestations of myelofibrosis and
earlier version of the manuscript and Daniel Hutta, Ph.D., of
appeared to be associated with an improvement Articulate Science for medical writing assistance with an early
in overall survival. Toxic effects were generally draft of the manuscript.
References
1. Tefferi A, Vaidya R, Caramazza D,

Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and
IL-15 levels are independently prognostic
in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol
2011;29:1356-63.
2. Cervantes F, Dupriez B, Pereira A, et al.
New prognostic scoring system for primary myelofibrosis based on a study of
the International Working Group for Myelofibrosis Research and Treatment. Blood
2009;113:2895-901.
3. Abdel-Wahab OI, Levine RL. Primary
myelofibrosis: update on definition, pathogenesis, and treatment. Annu Rev Med
2009;60:233-45.
4. Delhommeau F, Jeziorowska D, Marzac
C, Casadevall N. Molecular aspects of myeloproliferative neoplasms. Int J Hematol
2010;91:165-73.
5. Vainchenker W, Dusa A, Constantinescu SN. JAKs in pathology: role of Janus
kinases in hematopoietic malignancies
and immunodeficiencies. Semin Cell Dev
Biol 2008;19:385-93.
6. Quintás-Cardama A, Vaddi K, Liu P, et
al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: ther-

apeutic implications for the treatment of
myeloproliferative neoplasms. Blood 2010;
115:3109-17.
7. Verstovsek S, Kantarjian H, Mesa RA,
et al. Safety and efficacy of INCB018424,
a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363:1117-27.
8. Tefferi A, Vardiman JW. Classification
and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic
algorithms. Leukemia 2008;22:14-22.
9. Oken MM, Creech RH, Tormey DC, et
al. Toxicity and response criteria of the
Eastern Cooperative Oncology Group. Am
J Clin Oncol 1982;5:649-55.
10. Mesa RA, Kantarjian H, Tefferi A, et al.
Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a
JAK1 and JAK2 inhibitor (INCB018424)
clinical trial. Cancer 2011;117:4869-77.
11. Mesa RA, Kantarjian H, Tefferi A, et al.
Validation of the serial use of the Myelofibrosis Symptom Assessment Form
(MF-SAF) for measuring symptomatic improvement: performance in 86 myelofibrosis patients on INCB018424 clinical trial.

n engl j med 366;9

nejm.org

Blood 2009;114(22):3917. abstract.
12. Tefferi A, Barosi G, Mesa RA, et al. Inter
national Working Group (IWG) consensus
criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG
for Myelofibrosis Research and Treatment
(IWG-MRT). Blood 2006;108:1497-503.
13. Harris A, Kamishima T, Hao HY, et al.
Splenic volume measurements on computed tomography utilizing automatically contouring software and its relationship with
age, gender, and anthropometric parameters. Eur J Radiol 2010;75(1):e97-e101.
14. Mazonakis M, Damilakis J, Maris T,
Prassopoulos P, Gourtsoyiannis N. Estimation of spleen volume using MR imaging and a random marking technique. Eur
Radiol 2000;10:1899-903.
15. Prassopoulos P, Daskalogiannaki M,
Raissaki M, Hatjidakis A, Gourtsoyiannis
N. Determination of normal splenic volume on computed tomography in relation
to age, gender and body habitus. Eur Radiol 1997;7:246-8.
16. Harrison C, Kiladjian J-J, Al-Ali HK, et
al. JAK inhibition with ruxolitinib versus
best available therapy for myelofibrosis.
N Engl J Med 2012;366:787-98.
Copyright © 2012 Massachusetts Medical Society.

march 1, 2012

807

The New England Journal of Medicine
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on May 27, 2014. For personal use only. No other uses without permission.
Copyright © 2012 Massachusetts Medical Society. All rights reserved.

